Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.


Visfatin/NAMPT in Interstitial Pneumonia of Patients with Systemic Sclerosis and Scleroderma Mice Model Induced by Bleomycin.

Endo2,  Hirahito, Yamamoto1,  Tatsuhiro, Kaneko3,  Kaichi, Kusunoki3,  Yoshie, Kusunoki3,  Natsuko, Kawai3,  Shinichi

Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ohmori-nishi, Ohta-ku, Japan
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ohmori-nishi, Oh-taku, Japan
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine

Scleroderma intestinal lung disease(SLD) is a leading cause of morbidity and motality in patients with systemic sclerosis. Excessive fibrosis and inflammatory cell infiltration is a main features. Nicotinamide Phosphoribosyl Transferase/Visfatin (NAMPT/Visfatin) is an adipokine and a proinflammatory cytokine. To evaluate the significance of NAMPT/Visfatin in the diagnosis and monitoring of SLD we analyzed the concentration of NAMPT/Visfatin in bronchoalveolar lavage fluid (BALF) and plasma levels in SLD. Moreover we analyzed the role of NAMPT/Visfatin on experimental interstitial pneumonitis induced by bleomycin.

Methods:

NAMPT/Visfatin concentration of BAL fluids and plasma of patients with SSc and other CTD. 12 patients with SSc and 20 patients with other CTD-IP (PM/DM,RA). Concentration of NAMPT/Visfatin were measured by enzyme- linked immunoabsorbent assay. Expression of NAMPT/Visfatin in lung tissue detected by immunohistochemistry. Expression of NAMPT/Visfatin mRNA also detected by RT-PCR. We also analyzed the NAMPT/Visfatin expression on lung injury induced by bleomycin was investigated in mice.

Results:

Plasma concentration of NAMPT/Visfatin in SSc were significantly higher than healty subject (SLD 5.38 ±1.09, Control 2.38±2.60 ng/ml,P<0.05). NAMPT/Visfatin concentration in BALF of SLD were not significantly higher than that of other CTD (SLD11.8±6.3, CTD-LD18.9±4.4 ng/ml). NAMPT/Visfatin concentration in BALF were not correlated with total lung capacity, the diffusion capacity for carbon monoxide, whereas there were correlated of BAL lymphocyte counts and serum KL-6 levels. NAMPT/Visfatin detected in macrophage and pulmonary epithelial cells of biopsy tissues of interstitial pneumonitis of patients with SSc. NAMPT/Visfatin also detected in mice bleomycin induced interstitial pneumonitis at 3 weeks(serum IP 5.28±0.25,Control 1.8 ±0.68ng/ml, P<0.05). NAMPT/visfatin detected in pulmonary epithelial cells, macrophage, and endothelial cells in murine IP lung tissues by immunohistochemical analysis. NAMPT/Visfatin also detected in BALF in mice IP (IP 0.40±0.06 ng/ml, Control 0.18±0.12ng/ml). NAMPT/Visfatin augmented the proliferation of cultured lung fibrobrast derived from interstial peumonitis lung tissue. NAMPT/Visfatin also induced Col I, IL-6, and MCP-1 mRNA in cultured lung fibroblasts.

Conclusions:

These data suggest that Visfatin/NAMPT is a new therapeutic target of SLD.

To cite this abstract, please use the following information:
Endo, Hirahito, Yamamoto, Tatsuhiro, Kaneko, Kaichi, Kusunoki, Yoshie, Kusunoki, Natsuko, Kawai, Shinichi; Visfatin/NAMPT in Interstitial Pneumonia of Patients with Systemic Sclerosis and Scleroderma Mice Model Induced by Bleomycin. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :619
DOI: 10.1002/art.28387

Abstract Supplement

Meeting Menu

2010 ACR/ARHP